Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Responsibly' priced Invokana debuts in India

This article was originally published in Scrip

Executive Summary

Janssen has launched its selective sodium glucose co-transporter 2 (SGLT2) inhibitor Invokana (canagliflozin) for type 2 diabetes in India – sticking with its "commitment" of offering India-specific pricing for its products as far as possible.

You may also be interested in...



Janssen India MD To Depart

Significant leadership change is underway at J&J India, with Janssen India chief Sanjiv Navangul on his way out. He will be succeeded by senior J&J hand, Sarthak Ranade, who will need to handle some delicate issues pertaining to Sirturo while also keeping the flow of innovative products from the parent company to India going.

India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel